BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16708358)

  • 1. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Lin HC; Huang YH; Wu JC; Chiang JH; Lee PC; Lee SD
    Cancer; 2006 Jul; 107(1):141-8. PubMed ID: 16708358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey.
    Huo TI; Lin HC; Hsia CY; Wu JC; Lee PC; Chi CW; Lee SD
    Am J Gastroenterol; 2007 Sep; 102(9):1920-30. PubMed ID: 17573792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy.
    Huo TI; Huang YH; Lin HC; Wu JC; Chiang JH; Lee PC; Chang FY; Lee SD
    Am J Gastroenterol; 2006 May; 101(5):975-82. PubMed ID: 16573785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems.
    Huo TI; Hsia CY; Huang YH; Lin HC; Lee PC; Lui WY; Chiang JH; Chiou YY; Loong CC; Lee SD
    J Clin Gastroenterol; 2009 Sep; 43(8):773-81. PubMed ID: 19262404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis.
    Huo TI; Lin HC; Wu JC; Lee FY; Hou MC; Lee PC; Chang FY; Lee SD
    Liver Transpl; 2006 Jan; 12(1):65-71. PubMed ID: 16382473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
    Kudo M; Chung H; Osaki Y
    J Gastroenterol; 2003; 38(3):207-15. PubMed ID: 12673442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma.
    Limquiaco JL; Wong GL; Wong VW; Lai PB; Chan HL
    J Gastroenterol Hepatol; 2009 Jan; 24(1):63-9. PubMed ID: 19054256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.
    Kudo M; Chung H; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
    Hepatology; 2004 Dec; 40(6):1396-405. PubMed ID: 15565571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey.
    Huo TI; Lin HC; Hsia CY; Huang YH; Wu JC; Chiang JH; Chiou YY; Lui WY; Lee PC; Lee SD
    Dig Liver Dis; 2008 Nov; 40(11):882-9. PubMed ID: 18339595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
    Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Huang YH; Lee PC; Chang FY; Lee SD
    Liver Transpl; 2004 Dec; 10(12):1507-13. PubMed ID: 15558587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.
    Kitai S; Kudo M; Minami Y; Ueshima K; Chung H; Hagiwara S; Inoue T; Ishikawa E; Takahashi S; Asakuma Y; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
    Intervirology; 2008; 51 Suppl 1():86-94. PubMed ID: 18544953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.
    Huang YH; Chen CH; Chang TT; Chen SC; Wang SY; Lee HS; Lin PW; Huang GT; Sheu JC; Tsai HM; Lee PC; Chau GY; Lui WY; Lee SD; Wu JC
    J Gastroenterol Hepatol; 2005 May; 20(5):765-71. PubMed ID: 15853992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.
    Lv XH; Liu HB; Wang Y; Wang BY; Song M; Sun MJ
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1547-53. PubMed ID: 19686416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients.
    Yen YH; Changchien CS; Wang JH; Kee KM; Hung CH; Hu TH; Lee CM; Lin CY; Wang CC; Chen TY; Huang YJ; Lu SN
    Dig Liver Dis; 2009 Jun; 41(6):431-41. PubMed ID: 19185555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis.
    Nanashima A; Omagari K; Tobinaga S; Shibata K; Sumida Y; Mine M; Morino S; Shibasaki S; Ide N; Shindou H; Nagayasu T
    Eur J Surg Oncol; 2005 Oct; 31(8):882-90. PubMed ID: 15993031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis.
    Huo TI; Lin HC; Huo SC; Lee PC; Wu JC; Lee FY; Hou MC; Lee SD
    Liver Transpl; 2008 Jun; 14(6):837-44. PubMed ID: 18508377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy.
    Chen TW; Chu CM; Yu JC; Chen CJ; Chan DC; Liu YC; Hsieh CB
    Eur J Surg Oncol; 2007 May; 33(4):480-7. PubMed ID: 17129701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment.
    Vauthey JN; Ribero D; Abdalla EK; Jonas S; Bharat A; Schumacher G; Lerut J; Chapman WC; Hemming AW; Neuhaus P
    J Am Coll Surg; 2007 May; 204(5):1016-27; discussion 1027-8. PubMed ID: 17481532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.